Clinical Trial Update: Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating REGEND001 cell therapy for chronic obstructive pulmonary disease with diffusion capacity defect has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• REGEND001

Snippet

Sponsor: Regend Therapeutics | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED